Antitumor regimens with gemcitabine are safe for tumor patients with COVID-19. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text ...
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback